Absolutely agree.
The other salient characteristic of monogenic disorders is that they can be replicated in mouse models.
This what gives me confidence that the current Ph2 trials have a high chance of success.
I would be surprised if Neuren hasn't already run a batch of these mice tests on other indications - (it can certainly afford them).
I also wonder if Acadia has tested NNZ-2591 on Fragile-X mice, and perhaps even Retts-mice.
Would be interesting to know!
- Forums
- ASX - By Stock
- Ann: 2023 Results webinar
Absolutely agree.The other salient characteristic of monogenic...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.08 |
Change
0.140(1.08%) |
Mkt cap ! $1.682B |
Open | High | Low | Value | Volume |
$13.23 | $13.35 | $13.02 | $3.596M | 272.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 740 | $13.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.08 | 107 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 394 | 13.050 |
3 | 636 | 13.040 |
5 | 1369 | 13.030 |
7 | 4810 | 13.020 |
6 | 3053 | 13.010 |
Price($) | Vol. | No. |
---|---|---|
13.070 | 913 | 11 |
13.080 | 487 | 3 |
13.090 | 579 | 4 |
13.100 | 1837 | 8 |
13.110 | 861 | 6 |
Last trade - 14.55pm 14/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |